179 related articles for article (PubMed ID: 36471546)
21. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
[TBL] [Abstract][Full Text] [Related]
22. Nephron-sparing surgery for renal angiomyolipoma.
Heidenreich A; Hegele A; Varga Z; von Knobloch R; Hofmann R
Eur Urol; 2002 Mar; 41(3):267-73. PubMed ID: 12180227
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan.
Hatano T; Chikaraishi K; Inaba H; Endo K; Egawa S
Int J Urol; 2016 Oct; 23(10):833-838. PubMed ID: 27480662
[TBL] [Abstract][Full Text] [Related]
24. Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China.
Luo C; Zhang YS; Zhang MX; Chen MF; Li Y; Qi L; Li HZ; Zu XB; Cai Y
Orphanet J Rare Dis; 2021 Jul; 16(1):299. PubMed ID: 34217357
[TBL] [Abstract][Full Text] [Related]
25. Clinical and genetic analysis of tuberous sclerosis complex-associated renal angiomyolipoma in Chinese pedigrees.
Li S; Zhang Y; Wei J; Zhang X
Oncol Lett; 2017 Dec; 14(6):7085-7090. PubMed ID: 29344138
[TBL] [Abstract][Full Text] [Related]
26. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ
Br J Clin Pharmacol; 2016 May; 81(5):958-70. PubMed ID: 26580489
[TBL] [Abstract][Full Text] [Related]
28. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
[TBL] [Abstract][Full Text] [Related]
30. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Hatano T; Egawa S
Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574
[TBL] [Abstract][Full Text] [Related]
31. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.
Hatano T; Inaba H; Endo K; Egawa S
Int J Urol; 2017 Nov; 24(11):780-785. PubMed ID: 28905429
[TBL] [Abstract][Full Text] [Related]
32. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands.
Eijkemans MJ; van der Wal W; Reijnders LJ; Roes KC; van Waalwijk van Doorn-Khosrovani SB; Pelletier C; Magestro M; Zonnenberg B
Am J Kidney Dis; 2015 Oct; 66(4):638-45. PubMed ID: 26165440
[TBL] [Abstract][Full Text] [Related]
33. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
34. Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
Gu L; Peng C; Zhang F; Fang C; Guo G
Orphanet J Rare Dis; 2021 Jun; 16(1):277. PubMed ID: 34127034
[TBL] [Abstract][Full Text] [Related]
35. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
[No Abstract] [Full Text] [Related]
36. Laparoscopic aspiration for central renal angiomyolipoma: a novel technique based on single-center initial experience.
Xu B; Zhang Q; Jin J
Urology; 2013 Feb; 81(2):313-8. PubMed ID: 23374791
[TBL] [Abstract][Full Text] [Related]
37. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
[TBL] [Abstract][Full Text] [Related]
38. Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Luo C; Ye WR; Zu XB; Chen MF; Qi L; Li YL; Cai Y
Front Med (Lausanne); 2021; 8():744050. PubMed ID: 34901059
[No Abstract] [Full Text] [Related]
39. [HUGE RENAL ANGIOMYOLIPOMA (AML) IN TUBEROUS SCLEROSIS COMPLEX (TSC) WHICH IS CONTROLED BY EVEROLIMUS: A CASE REPORT].
Kanbara T; Sakaeda K; Kusaka N; Akebi N
Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):54-58. PubMed ID: 28132993
[TBL] [Abstract][Full Text] [Related]
40. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]